AN2 Therapeutics, Inc.

US$4.00As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ANTXHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (25.01%)
Div yield —
ROE (50.12%)
Biotechnology
Beta (5Y) (0.94)
PE TTM —
TSR TTM 225.20%
Mkt cap US$150.9M
ROIC (33.51%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.09
27.20%
(8.67%)
Hold 0|12|8|11|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.04
12.68%
12.45%
19.46%
5.41%
Revenue$M
19.24
19.97
20.19
21.13
5.67%
3.47%
3.71%
8.52%
Peers (US$150.9M)
Cap (US$)
PE
148.4M
—
Capital
TTM
5Y
10Y
Leveragex
1.796
(1.935)
(1.615)
EBIT/Intx
0.895
0.096
0.095
Own earn%
232.03
(194.23)
(153.62)
Sh yield%
27.39
27.84
29.16
Owners
Insiders/Inst%
6.14
89.24
Short interest%
2.62
SBC / revenue%
5.82
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
20–26
$1 testx
—
Incr. ROIC%
4